Electra Therapeutics Secures $183m for sHLH Drug
Electra Therapeutics has raised $183 million in a Series C financing round to support its phase 2/3 trial of ELA026, a potential therapy for secondary hemophagocytic lymphohistiocytosis (sHLH), a rare inflammatory disease.
The trial, which is currently enrolling patients in the US and Europe, aims to evaluate the efficacy of ELA026, an anti-SIRP-antibody, in treating sHLH, a hyperinflammatory disease triggered by illnesses such as infections, autoimmune diseases, or cancer.
Other biotech companies, including Hemab, Zag Bio, Elevara, Expedition, and Curve, have also secured new funding.
No statement from the company is available.
Author's summary: Electra Therapeutics raises $183m for sHLH drug trial.
More News
- 'Love Island's' Huda Mustafa Apologizes After Laughing At Racist Slur Hurled Towards Olandria Carthen
- Post-Profit Antitrust | Yale Law Journal
- Pras Michel Must Forfeit $64 Million After Criminal Convictions in Foreign Influence Case
- Bam Adebayo's evolution into 'three-level scorer' starts with Heat's new offense
- Stephen A. Smith Questions Why Chris Grier Got Fired Before Mike McDaniel After Dolphins' Embarrassing Loss
- Wemby’s Evolution Is Scary: Spurs Phenom Dominates Again, Leaves Heat Defenders Helpless
- Bose headphones and earbuds return to all-time lows for Black Friday
- No Giannis, No Problem — Bucks Take Down Warriors as Antetokounmpo Steals the Show in Minion Costume
- Why Ryan Rollins loved Draymond Green coming for him after Stephen Curry incident
- Patriots' Rhamondre Stevenson is out for Sunday's game vs Falcons